Literature DB >> 28611481

IBD: Phase II trial success for anti-MADCAM1 antibody.

Iain Dickson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28611481     DOI： 10.1038/nrgastro.2017.82

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Séverine Vermeire; William J Sandborn; Silvio Danese; Xavier Hébuterne; Bruce A Salzberg; Maria Klopocka; Dino Tarabar; Tomas Vanasek; Miloš Greguš; Paul A Hellstern; Joo Sung Kim; Miles P Sparrow; Kenneth J Gorelick; Michelle Hinz; Alaa Ahmad; Vivek Pradhan; Mina Hassan-Zahraee; Robert Clare; Fabio Cataldi; Walter Reinisch
Journal:  Lancet       Date:  2017-05-17       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.